Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ESRRG | P62508 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22939679 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2ESRRGCA2LMNAALDH1A1 | |
| SCHEMBL22939048 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2ESRRGCA2LMNAALDH1A1 | |
| SCHEMBL29780254 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2ESRRGCA2LMNAALDH1A1 | |
| SCHEMBL22939676 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2ESRRGCA2LMNAALDH1A1 | |
| SCHEMBL21163666 | 0.99 | ESRRG (0.51) | SMN1; SMN2ESRRGCA2LMNAALDH1A1 | |
| SCHEMBL23832608 | 0.91 | ALDH1A1 (0.52) | SMN1; SMN2ESRRGCA2LMNAALDH1A1 | |
| SCHEMBL750337 | 0.90 | ESRRG (0.56) | ESRRGCA2LMNAALDH1A1SLC22A2 | |
| SCHEMBL4257896 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2CA2ALDH1A1CA12CA1 | |
| SCHEMBL3758446 | 0.88 | ESRRG (0.53) | ESRRGCA2LMNAALDH1A1SLC22A2 | |
| SCHEMBL29780267 | 0.88 | ESRRG (0.53) | ESRRGCA2LMNAALDH1A1SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624038-B2 | Molecules and methods related to treatment of uncontrolled cellular proliferation | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220251097-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2022-08-11 | — | — | US | disclosed |
| WO-2021022076-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251097-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | MKI67, BCL2, PCNA | SMN1; SMN2 2560/4885ESRRG 1684/4885CA2 1559/4885 |
| US-12624038-B2 | Molecules and methods related to treatment of uncontrolled cellular proliferation | CCNC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MKI67 | SMN1; SMN2 4430/4885ESRRG 3141/4885CA2 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.